Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients.

CCPB use in CKD stage 5 patients was associated with a significantly increased cardiovascular event risk compared with the nonusers, whereas the all-cause mortality risk was similar between the two groups. Whether these relationships are causal require further randomized controlled trials.